Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy — ARISE

Drug-resistant Epilepsy Clinical Trial

Official title:
A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy

Status Completed

Clinical Trial Summary

The purpose of the study is to characterize the dose-response relationship with respect to efficacy of Padsevonil administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03373383
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 2
Start date	February 12, 2018
Completion date	January 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03893916` - MEG Versus EEG HR for the Localization of the Epileptogenic Zone as Part of the Pre-surgical Assessment of Epilepsy	N/A
Terminated	`NCT03739840` - A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy	Phase 3
Terminated	`NCT03370120` - Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy	Phase 2
Recruiting	`NCT05769634` - Electrophysiological Read-Out of Interoceptive Processing	Early Phase 1